Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.
路透社2026/10/08 12:56The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Stock information has been added in the second paragraph, detailed information has been added in the fifth, eighth, and ninth paragraphs, and background information has been added in the sixth, seventh, tenth, and eleventh paragraphs.
Reuters, October 8 - Pharmaceutical company Viatris VTRS.O will acquire Pacira BioSciences PCRX.O in an all-cash deal valued at $1.65 billion, adding two non-opioid pain medications to its portfolio, the two companies announced on Thursday.
Viatris will acquire Pacira for $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s shares rose 44% in premarket trading.
Pacira’s non-opioid pain medications, Exparel and Zilretta,
had 2025 sales of $575.1 million and $116.6 million, respectively. Exparel is used for the treatment of acute post-surgical pain, while Zilretta is used to treat pain associated with knee osteoarthritis.
Viatris said it expects to expand the reach of these products in certain target markets.
Viatris CEO Scott Smith stated in a press release that the addition of these drugs “creates synergy with the market opportunity for our rapid-onset meloxicam and positions us as a leader in the non-opioid pain treatment field.”
The U.S. Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-onset meloxicam to treat moderate to severe acute pain.
Viatris plans to primarily fund this acquisition with available cash, with the remainder raised via short-term borrowing. The company stated the transaction has a minimal impact on its total leverage ratio.
In August, Viatris (link) raised its annual adjusted profit forecast, as it counted on strong sales of branded drugs and growth in the Chinese market.
The pharmaceutical company previously faced setbacks in its Indian operations (link), including manufacturing issues such as a fire at its plant in Nashik, western India, and intensifying competition in the generic drug market, raising concerns over the growth and resilience of its core business.
The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics.
(For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of translated texts. The automated translations are provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss that may result from using the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
